期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

骨质疏松症药物治疗进展 被引量：4

Advances in Medication of Osteoporosis
下载PDF
导出
摘要 近年来骨质疏松症的药物治疗研究有了很大进展,主要分为骨吸收抑制剂和骨形成促进剂两大类。在此主要介绍原发性骨质疏松症的药物治疗进展。 The studies on medication of osteoporosis have achieved obvious advances lately. The drugs mostly include bone absorptionin-hibitor drugs and bone formation- acceleration drugs. This review mostly elucidates advances in medication of primary osteoporosis.
作者 蒋利华
机构地区 重庆医科大学附属第一医院
出处 《中国药业》 CAS 2006年第4期3-5,共3页 China Pharmaceuticals
关键词 骨质疏松症 骨吸收抑制剂 骨形成促进剂 osteoporosis bone absorption - inhibitor drugs bone formation - acceleration drugs
分类号 R681 [医药卫生—骨科学]
  • 相关文献

参考文献23

  • 1Lozo P,Krpan D,Krvavica A,et al.Bone histology in postmenopausal osteoporosis-variations in cellular activity[J].Act Med Croatica,2004,58 (1):5-11.
  • 2Wells G,Tugwell P,Shea B,et al.Meta-analyses of therapies for postmenopausal osteoporosis.V.Meta-analyses of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women[J].Endocr Rev,2002,23:529-539.
  • 3Rossouw JE,Anderson GL,Prentice RL,et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the Women's Health Initiative randomized controlled trial[J].JAMA,2002,288:321-333.
  • 4Potter SM,Baum JA,Teng H,et al.Soy protein and isoflavonesl:their effects on blood lipids and bone density in postmenopausal women[J].AMJ Clin Nutr,1998,68(Suppl):1 375 S-1 379 S.
  • 5Ettinger B,Black DM,Mitlak BH,et al.Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene:results from a 3-year randomized clinical trial[J].JAMA,1999,282:637-645.
  • 6Cummings SR,Eckert S,Krueger KA,et al.The effect of raloxifene on risk of breast cancer in postmenopausal women:results from the MORE randomized trial[J].JAMA,1999,281:2189 -2 197.
  • 7Muller K,Wiesenberg I,Jaeggi K,et al.Effects of the bisphosphonate zoledronate on bone loss in theovariectomized and in the adjuvant arthritic rat[J].Arzneimittelforschung,1998 (48):81-86.
  • 8Pols HA,Hanley D,Stepan J,et al.Multinational placebo -controlled randomozed on bone density and fracture risk in postmenopausal women with low bone mass:results of the FOSIT Study[J].Osteoporosis Int,1999,9(5):461-486.
  • 9Black DM,Thompson DE,Bauer DC,et al.Fracture risk reduction with alendronat in women with osteoporosis:the fractures intervention trial[J].Clin Endo Crinol Metab,2000,85 (11):4 118-4 125.
  • 10Ensrud KE,Barrett-Connor EL,Schwartz A,et al.Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD:results from the Fracture Intervention Trial long-term extension[J].J Bone Miner Res,2004,19:1 259-1 269.

同被引文献55

引证文献4

二级引证文献2

中国药业
2006年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部